Loading quotes...

Forecast

The analysts' average price target is €4.54 (-19.93%). The median is €4.54 (-19.93%).

Buy
  0
Hold
  2
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Embecta exceeds Q3 expectations and raises full-year outlook

    Embecta reported adjusted EPS of $0.56 and revenue of $271.7 million for Q3 2026, significantly beating consensus estimates. The company raised its forecasts for adjusted operating margin to 23.5–24% and adjusted EPS to $1.80–1.90, but left its 2026 revenue guidance unchanged. Despite a year‑over‑year revenue decline, Embecta benefited from cost cuts, the contribution from the acquisition of Owen Mumford and a sequential improvement in results; however, the U.S. business remains under pressure. » More on de.investing.com


  • Embecta resets U.S. outlook after retailer share loss and pushes GLP-1, Owen Mumford diversification

    Embecta cut its U.S. guidance after a challenging quarter marked by loss of shelf position at a major retailer—attributed mainly to price pressure—softer insulin pen prescriptions and inventory adjustments. CEO Devdatt Kurdikar said the company is assessing whether the weakness is temporary or structural amid rising GLP-1 affordability and insurance changes. Embecta is accelerating diversification via lower‑priced pen needles and syringes, a GLP‑1 B2B channel and the pending Owen Mumford acquisition while targeting about $100 million in free cash flow and prioritizing debt reduction and buybacks. » More on finance.yahoo.com


  • S&P downgrades Embecta to B after sales decline in pen needles

    S&P Global Ratings cut Embecta’s rating from B+ to B with a stable outlook after second fiscal quarter sales fell 14%. Reasons cited include roughly 20% currency‑adjusted revenue weakness in insulin pen needles, market share losses to a lower‑priced competitor, and weaker US market demand (lower insulin usage, a shift to cheaper channels, increased use of automated systems and GLP‑1 drugs). S&P expects about a 6% sales decline in 2026, an adjusted margin down roughly 800 basis points to 29%, and leverage of 4.5–5x; the acquisition of Owen Mumford is expected to be financed via the revolving credit facility and the dividend will be cut to reduce debt. » More on de.investing.com


  • Embecta misses Q2 2026 forecasts significantly, stock falls 44% premarket

    Embecta reported Q2 2026 EPS of $0.27 versus $0.42 expected and revenue of $221.8 million versus $235.66 million expected. Revenue fell 14.4% year-on-year, driven by a 29.4% decline in the US business, prompting the company to lower its full-year guidance. The stock plunged in premarket trading from $9.25 to $5.15. Management announced a review of the cost and organizational structure, brand and product initiatives, and the integration of Owen Mumford as a strategic move. » More on de.investing.com


  • Embecta to acquire Owen Mumford for up to ÂŁ150 million

    Embecta has signed a definitive agreement to acquire British medical‑technology manufacturer Owen Mumford. On closing Embecta will pay £100 million in cash plus up to £50 million in contingent payments, depending on net sales of the Aidaptus autoinjector platform in the three years after closing. Owen Mumford recorded net sales of £69.4 million in 2025; the transaction is expected to close in the third quarter of fiscal 2026, subject to regulatory approvals. Embecta expects growth and long‑term accretion from 2027 but foresees a dilution of adjusted net income in 2027; financing will be partly provided through its revolving credit facility. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Embecta Aktie has already paid €0.15 in dividends. The last payout was in September.

Financials

In the last quarter, Embecta Aktie had revenue of €238.07m and net profit of €18.49m
(EUR) June 2026
YoY
Revenue 238.07m 5.04%
Gross profit 134.32m 18.81%
Net profit 18.49m 52.11%
EBITDA 56.69m 39.58%

Fundamentals

Metric Value
Market capitalization
€332.62m
Number of shares
56.66m
52-week high/low
€13.46 - €2.52
Dividend yield
4.87%
Dividends TTM
€0.28
Beta
0.81
P/E ratio
4.34
PEG ratio
0.88
P/B ratio
-0.62
P/S ratio
0.36

Company profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Name
Embecta Aktie
CEO
Devdatt Kurdikar
Headquarters Parsippany, nj
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
22/03/2022
Employees 1,850

Ticker symbols

Exchange Symbol
NASDAQ
EMBC
Frankfurt
JX7.F
DĂĽsseldorf
JX7.DU
MĂĽnchen
JX7.MU
🍪

Parqet  uses cookies. Learn more